M2e/NP-ISS: Completed Phase I enrollment

Dynavax completed enrollment of 39 healthy volunteers in a Phase I trial evaluating 2 doses of N8295 given monthly. N8295 is a component of Dynavax's Universal flu vaccine. Novartis AG (NYSE:NVS; SIX...